Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Neuroblastoma Clinical Trial

Official title:

Phase I/II Multicenter Study to Assess Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05429502
• Other study ID #: CLEE011Q12101
• Secondary ID: 2021-005617-14
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: December 27, 2022
• Est. completion date: January 29, 2029

Study information

• Verified date: May 2024
• Source: Novartis
• Contact: Novartis Pharmaceuticals
• Phone: 1-888-669-6682
• Email: novartis.email[@]novartis.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase I/II study to assess the efficacy and safety of ribociclib in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory (r/r) neuroblastoma (NB), and other solid tumors, including medulloblastoma (MB), high-grade glioma (HGG), malignant rhabdoid tumors (MRT), and rhabdomyosarcoma (RMS).

Description:

The study consists of Phase I -part A (dose finding) and Phase I - part B (multiple expansion cohorts). Phase II may begin after evaluation of Phase I data (safety, tolerability, efficacy, pharmacokinetics and biomarker data), with consideration of other emerging data that may impact on the treatment landscape, before initiating Phase II in patients with relapsed or refractory NB and/or other tumors studied in Phase I.

• Phase I-Part A (dose finding): a dose finding to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of ribociclib in combination with TOTEM.

• Phase I- Part B (multiple expansion cohorts): it will be initiated to confirm RP2D identified from Phase I-part A. Multiple expansion cohorts have been planned to assess the preliminary antitumor activity and safety of ribociclib in combination with TOTEM in participants with r/r NB (cohort 1), MB (cohort 2), HGG (cohort 3), MRT (cohort 4), and RMS (cohort 5)

• Phase II- Double-blind, randomized, placebo controlled in r/r NB: It is a two-arm randomized, double blinded, placebo controlled, parallel group trial in participants with r/r NB.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 231
• Est. completion date: January 29, 2029
• Est. primary completion date: October 16, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Months to 21 Years

Eligibility

Inclusion Criteria:

1. Participants and/or guardian have the ability to understand and the willingness to sign a written informed consent document.

2. Age = 12 months and = 21 years at the time of signing consent form Note: The first dose level of Phase I - part A (dose finding) will enroll participants = 12 years - 21 years old, and may expand to younger participants (= 12 months to < 12 years) as determined by the data.

3. Histologically or cytologically confirmed solid tumors listed below that have progressed despite standard therapy or for which no effective standard therapy exists.

1. Neuroblastoma (for Phase I and Phase II): Histologically proven neuroblastoma as per International Neuroblastoma Staging System (INSS); Relapsed or refractory disease; Measurable disease per International Neuroblastoma Response criteria (INRC); Bone marrow only disease not eligible; Available MYCN status before screening

2. Medulloblastoma (for Phase I) regardless of genetic status (i.e. Groups 3 or 4 WNT-activated or non-WNT, SHH-activated or non-SHH)

3. High-grade glioma (for Phase I): including HGG NOS, WHO Grade III or Grade IV; Glioblastoma, IDH-wildtype or IDH-mutant; Anaplastic astrocytoma, IDH-mutant; Anaplastic oligodendroglioma, IDH-mutant; Anaplastic pleomorphic xanthoastrocytoma; Diffuse midline gliomas, H3 K27-altered; Diffuse hemispheric glioma, H3 G34-mutant; Diffuse pediatric-type HGG, H3-wildtype and IDH-wildtype.

4. Malignant rhabdoid tumor (for Phase I) includes diagnoses of atypical teratoid/rhabdoid tumor (AT/RT), and rhabdoid tumor of the kidney (RTK), and other soft tissues as defined by 2 of the 3 following criteria; either (1)+(2) or (1)+(3): (1) Morphology and immunophenotypic panel consistent with rhabdoid tumor; (2) Loss of SMARCB1 confirmed by immunohistochemistry; (3) Molecular confirmation of tumor-specific bi-allelic SMARCB1 loss/mutation is encouraged in cases where SMARCB1 immunohistochemistry is equivocal, and required if SMARCB1 immunohistochemistry is not available

5. Rhabdomyosarcoma (for Phase I) independent of fusion status and subtype

4. Participants with CNS disease who are on corticosteroids should take stable doses for at least 7 days prior to first dose of ribociclib with no plans for escalation.

5. Performance status:

1. = 16 years: Lansky Play score = 50%

2. >16 years: Karnofsky performance status = 50% or ECOG < 3

6. Life expectancy of = 12 weeks at the time of enrollment

7. Adequate bone marrow function (bone marrow may be involved with tumor) and organ function

8. Adequate hepatic, renal, cardiac function

9. Females who are sexually active must agree to use highly effective contraception during and for 6 months after treatment. Additionally, females of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of study medication. Pregnant or lactating females are not eligible for the study.

10. Sexually active males (including those that have had a vasectomy), who do not agree to abstinence, must be willing to use a condom during intercourse while on study treatment and for 6 months after stopping treatment.

Exclusion Criteria:

1. Known hypersensitivity to any of the excipients of ribociclib or topotecan or temozolomide.

2. Not recovered from clinical and laboratory acute toxicities related to prior anti-cancer therapies

3. Concurrent severe and/or uncontrolled concurrent medical conditions (serious infections or significant cardiac, pulmonary, hepatic, psychiatric, GI disease, or other organ dysfunction) that in the investigator's judgement could compromise their ability to tolerate or absorb protocol therapy or would interfere with the study procedures or results

4. Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality

5. History of QTc prolongation; taking medications with a known risk to prolong the QT interval hat cannot be discontinued or replaced by safe alternative medication

6. Currently taking medications that are mainly metabolized by CYP3A4/5 with a narrow therapeutic index, strong inducers or inhibitors of CYP3A4/5, herbal preparations/medications and dietary supplements

7. Vaccinated with live, attenuated vaccines within 4 weeks

8. Participated in a prior investigational study within 30 days

9. Received prior treatment with a CDK4/6 inhibitor

10. Received last dose of anticancer therapy (including experimental) within 4 weeks

11. Previous myeloblative therapy with autologous hematopoietic stem cell rescue within 8 weeks

12. Allogeneic stem cell transplant within 3 months

13. Has last fraction of radiation within 4 weeks

14. Major surgery within 2 weeks

15. Pregnant or nursing (breast feeding) female participant or female participant who plans to become pregnant or breast-feed during the trial.

Other protocol-defined inclusion/exclusion criteria may apply

Related Conditions & MeSH terms

• Neuroblastoma

Intervention

Drug:
• Topotecan
Starting out dose of topotecan administered at standard dose given to neuroblastoma patients (0.75 mg/m2/day).
• Temozolomide
Starting out dose of temozolomide for first two cohorts for Phase 1-Part A: 150mg/m2/day. Starting out dose for subsequent cohorts in Phase 1-Part A will initiate at 100mg/m2/day and will be determined for Phase 1-Part B depending on safety outcome and for phase II.
• Ribociclib
Ribociclib administered at the RP2D defined from Phase I-Part A.

Locations

Country	Name	City	State
Australia	Novartis Investigative Site	Randwick	New South Wales
France	Novartis Investigative Site	Villejuif
Germany	Novartis Investigative Site	Koeln
Italy	Novartis Investigative Site	Milano	MI
Singapore	Novartis Investigative Site	Singapore
Singapore	Novartis Investigative Site	Singapore
Spain	Novartis Investigative Site	Barcelona	Catalunya
United States	Dana Farber Cancer Institute .	Boston	Massachusetts
United States	St Jude s Childrens Research Hospital Dept of Regulatory	Memphis	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals	Innovative Therapies For Children with Cancer Consortium

Countries where clinical trial is conducted

United States,  Australia,  France,  Germany,  Italy,  Singapore,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1- Part A: Percentage of participants with Dose Limiting Toxicities (DLTs) in Cycle 1	Percentage of participants with DLTs during first cycle of treatment (each cycle is 28 days) for each dose level associated with administration of ribociclib in combination with topotecan and temozolomide.; A DLT is defined as an adverse event or abnormal laboratory value suspected to be related with study treatment.	Up to 28 days
Primary	Phase I- Part B: Overall response rate (ORR) as assessed by Blinded Independent Review Committee (BIRC)	ORR defined as the percentage of participants with confirmed best overall response of complete response (CR) or partial response (PR) as assessed by BIRC per: Revised Assessment in Neuro-Oncology (RANO) criteria for participants with HGG; International Neuroblastoma Response Criteria (INRC) for participants with NB; Response evaluation criteria in solid tumors (RECIST) version 1.1 for participants with MB, MRT and RMS	Up to 12 months
Primary	Phase II- ORR as assessed by BIRC	ORR defined as the percentage of participants with confirmed best overall response of CR or PR as assessed by BIRC using INRC	Up to 12 months
Secondary	Plasma concentrations of ribociclib (Phase I-Part A, Phase I-Part B, Phase II)	Pharmacokinetic (PK) blood samples will be collected at selected time-points to determine ribociclib plasma concentrations from participants in Phase I-Part A, Phase I-Part B and Phase II	Cycle 1 day 1 and 15; Cycle 2 Day 15. Cycle=28 days
Secondary	Area under the plasma concentration-time curve (AUC) of ribociclib (Phase I-Part A, Phase I-Part B, Phase II)	PK blood samples will be collected at selected time-points to determine AUC of ribociclib from participants in Phase I-Part A, Phase I-Part B and Phase II	Cycle 1 day 1 and 15; Cycle 2 Day 15. Cycle=28 days
Secondary	Maximum plasma concentration (Cmax) of ribociclib (Phase I-Part A, Phase I-Part B, Phase II)	PK blood samples will be collected at selected time-points to determine Cmax of ribociclib from participants in Phase I-Part A, Phase I-Part B and Phase II	Cycle 1 day 1 and 15; Cycle 2 Day 15. Cycle=28 days
Secondary	Time of maximum plasma concentration (Tmax) of ribociclib (Phase I-Part A, Phase I-Part B)	PK blood samples will be collected at selected time-points to determine Cmax of ribociclib from participants in Phase I-Part A and Phase I-Part B.	Cycle 1 day 1 and 15; Cycle 2 Day 15. Cycle=28 days
Secondary	Duration of response (DOR) as assessed by BIRC (Phase I-Part B)	Duration of response is defined as the time from the date of the first documented response (CR or PR) to the date of first documented progression, or death due any cause. DOR will be assessed by BIRC per RANO for participants with HGG, INRC for participants with NB and RECIST 1.1 for participants with MB, MRT and RMS for participants in Phase I-Part B.	Up to 42 months
Secondary	Progression Free Survival (PFS) as assessed by BIRC (Phase I-Part B)	PFS is defined as the time from the date of start of treatment to the first documented progression or death due to any cause. PFS will be assessed by BIRC per RANO for participants with HGG, INRC for participants with NB and RECIST 1.1 for participants with MB, MRT and RMS for participants in Phase I-Part B.	Up to 42 months
Secondary	Time to response (TTR) as assessed by BIRC (Phase I-Part B)	TTR is defined as the time from the date of start of treatment to the first documented progression of either CR or PR. TTR will be assessed by BIRC per RANO for participants with HGG, INRC for participants with NB and RECIST 1.1 for participants with MB, MRT and RMS for participants in Phase I-Part B.	Up to 42 months
Secondary	Overall survival (Phase I-Part B)	OS is defined as the time from the date of start of treatment to the date of death, due to any cause. OS will be assessed for participants in Phase I-Part B.	Up to 42 months
Secondary	Percentage of participants with dose interruptions and dose reductions (Phase I-Part A, Phase I-Part B, Phase II)	Percentage of participants with dose interruptions and dose reductions for participants in Phase I-Part A, Phase I-Part B and Phase II	Up to 12 months
Secondary	Duration of response (DOR) as assessed by BIRC (Phase II)	Duration of response is defined as the time from the date of the first documented response (CR or PR) to the date of first documented progression, or death due any cause. DOR will be assessed by BIRC per RECIST 1.1 for participants in Phase II.	Up to 42 months
Secondary	Progression Free Survival (PFS) as assessed by BIRC (Phase II)	PFS is defined as the time from the date of start of treatment to the first documented progression or death due to any cause. PFS will be assessed by BIRC per INRC for participants in Phase II	Up to 42 months
Secondary	Time to response (TTR) as assessed by BIRC (Phase II)	TTR is defined as the time from the date of start of treatment to the first documented progression of either CR or PR. TTR will be assessed by BIRC per INRC for participants in Phase II	Up to 42 months
Secondary	Clinical benefit rate (CBR) as assessed by BIRC (Phase II)	CBR is defined as the percentage of participants with a best overall response of CR, PR or an overall response of stable disease lasting for a duration of at least 24 weeks. CBR will be assessed by BIRC per INRC for participants in Phase II	Up to 42 months
Secondary	Overall survival (OS) (Phase II)	OS is defined as the time from the date of start of treatment to the date of death, due to any cause. OS will be assessed for participants in Phase II	Up to 42 months
Secondary	Change from baseline in Pediatric Quality of Life Inventory (PedsQL) questionnaire (Phase II)	PedsQL is a generic instrument used to measure health related quality of life (HRQOL) in children and youth aged 0-25 years. The generic core instrument is available for different age groups and consist of 23 items covering 4 dimensions of HRQOL: Physical functioning (8 items), Emotional Functioning (5 items), Social Functioning (5 items) and School Functioning (5 items). Items are scored on a 5 point Likert-type response scale: 0=never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; and 4=almost always a problem). Items are reverse scored and linearly transformed to a 0-100 scale, where higher scores indicating better QoL. Change from baseline in PedsQL scores will be assessed for participants in Phase II.	Up to 42 months